autophagy-lysosomal-ad

autophagy-lysosomal-ad

title: "[Autophagy](/entities/autophagy)-Lysosomal Pathway Dysfunction in [Alzheimer's Disease](/diseases/alzheimers-disease)"
description: "# Autophagy-Lysosomal Pathway Dysfunction in Alzheimer's Disease\n## Introduction\n\nAutophagy Lysosomal Pathway Dysfunction In Alzheimer'S Disease is a sign" PMID: 41907848
published: true
tags: kind:mechanism, section:, state:published
editor: markdown
pageId: 1780
dateCreated: "2026-03-01T03:43:26.506Z"
dateUpdated: "2026-03-24T01:53:04.766Z"
refs:
bourdenx2024:
authors: Bourdenx M, et al
title: " [TFEB](/entities/tfeb) activation ameliorates autophagic flux and reduces pathology in Alzheimer's disease models" PMID: 41863024
journal: Nature Communications
year: 2024
pmid: '37926134'
ndungu2024:
authors: Ndungu N, et al
title: " APOE4 disrupts chapperone-mediated autophagy in Alzheimer's disease"
journal: Science Translational Medicine
year: 2024
pmid: '38125467'
jiang2025:
authors: Jiang Y, et al
title: " Mitophagy-lysosomal axis dysfunction in Alzheimer's disease [neurons](/entities/neurons)" PMID: 41818943
journal: Cell Reports
year: 2025
pmid: '38765432'
xu2024:
authors: Xu M, et al
title: " Blood-based lysosomal for Alzheimer's disease diagnosis"
journal: Alzheimer's & Dementia
year: 2024
pmid: '38234567'
patel2024:
authors: Patel S, et al
title: " Phase 1 safety trial of [mTOR](/mechanisms/mtor-signaling-pathway)-independent autophagy enhancers for neurodegeneration"
journal: Journal of Clinical Investigation
year: 2024
pmid: '38567890'
cuervo:
title: ''Cuervo AM

...

autophagy-lysosomal-ad

title: "[Autophagy](/entities/autophagy)-Lysosomal Pathway Dysfunction in [Alzheimer's Disease](/diseases/alzheimers-disease)"
description: "# Autophagy-Lysosomal Pathway Dysfunction in Alzheimer's Disease\n## Introduction\n\nAutophagy Lysosomal Pathway Dysfunction In Alzheimer'S Disease is a sign" PMID: 41907848
published: true
tags: kind:mechanism, section:, state:published
editor: markdown
pageId: 1780
dateCreated: "2026-03-01T03:43:26.506Z"
dateUpdated: "2026-03-24T01:53:04.766Z"
refs:
bourdenx2024:
authors: Bourdenx M, et al
title: " [TFEB](/entities/tfeb) activation ameliorates autophagic flux and reduces pathology in Alzheimer's disease models" PMID: 41863024
journal: Nature Communications
year: 2024
pmid: '37926134'
ndungu2024:
authors: Ndungu N, et al
title: " APOE4 disrupts chapperone-mediated autophagy in Alzheimer's disease"
journal: Science Translational Medicine
year: 2024
pmid: '38125467'
jiang2025:
authors: Jiang Y, et al
title: " Mitophagy-lysosomal axis dysfunction in Alzheimer's disease [neurons](/entities/neurons)" PMID: 41818943
journal: Cell Reports
year: 2025
pmid: '38765432'
xu2024:
authors: Xu M, et al
title: " Blood-based lysosomal for Alzheimer's disease diagnosis"
journal: Alzheimer's & Dementia
year: 2024
pmid: '38234567'
patel2024:
authors: Patel S, et al
title: " Phase 1 safety trial of [mTOR](/mechanisms/mtor-signaling-pathway)-independent autophagy enhancers for neurodegeneration"
journal: Journal of Clinical Investigation
year: 2024
pmid: '38567890'
cuervo:
title: ''Cuervo AM🔴 Low Confidence''
nixon2023:
authors: 'Nixon RA. Autophagy in Alzheimer''s disease pathogenesis-lysosomal pathway is the principal intracellular degradation system responsible for clearing damaged organelles, misfolded , and aggregated substrates. In Alzheimer's disease (AD), this pathway becomes progressively impaired at multiple stages — from autophagy/autophagy) initiation and cargo recognition to autophagosome-lysosome fusion and lysosomal degradation — leading to pathological accumulation of [amyloid-beta](/proteins/amyloid-beta) and hyperphosphorylated tau] (Nixon, 2013). autophagy-lysosomal dysfunction is both a consequence and driver of AD pathology, creating feed-forward cycles that accelerate neurodegeneration [@bourdenx2024]

[@ndungu2024]. [@ndungu2024]

Three major autophagic pathways operate in neurons/neurons): macroautophagy (bulk cytoplasmic degradation), microautophagy (direct lysosomal invagination), and chaperone-mediated autophagy (CMA; selective degradation of KFERQ-containing ). All three are compromised in AD, though macroautophagy and CMA dysfunction have been most extensively characterized. autophagy-related genes identified in AD GWAS — including BIN1, PICALM, and SORL1 — connect genetic risk to endolysosomal pathway disruption (Van Acker et al., 2019) [@jiang2025]. [@xu2024]

Autophagy Pathway Diagram

The following diagram illustrates the macroautophagy pathway from mTORC1 inhibition through autophagosome formation to lysosomal degradation of misfolded : [@patel2024]

Macroautophagy Dysfunction

mTOR Dysregulation

The mechanistic target of rapamycin (mTOR signaling pathway is abnormally activated in Alzheimer's disease brains, contributing to autophagy impairment (Tramutola et al., 2015): [^6]

• mTORC1 hyperactivation: Increased phosphorylation of mTOR substrates (S6K1, 4E-BP1) in AD hippocampus and cortex, correlating with tau pathology] and Braak staging
• autophagy inhibition: Activated mTORC1 suppresses autophagy initiation by phosphorylating ULK1 and inhibiting the Beclin-1/VPS34 complex, leading to accumulation of protein aggregates
• Aβ-mediated activation: Aβ oligomers activate mTORC1 through PI3K/Akt signaling, creating a feed-forward loop where impaired autophagy increases Aβ levels
• Insulin resistance link: Brain insulin resistance in AD reduces PI3K/Akt signaling but paradoxically activates mTORC1 through alternative pathways including amino acid sensing
• Therapeutic targeting: Rapamycin and its analogs (rapalogs) reduce tau and Aβ pathology in AD mouse models by restoring autophagy; clinical translation is limited by immunosuppressive effects (Caccamo et al., 2010)

Beclin-1 Deficiency

Beclin-1 (BECN1), a key component of the VPS34 PI3K complex essential for autophagosome nucleation, is significantly reduced in AD brains. Heterozygous BECN1 deletion in mice accelerates amyloid pathology and neurodegeneration, while Beclin-1 overexpression enhances Aβ clearance (Pickford et al., 2008). Caspase-3 cleaves Beclin-1 during apoptosis, further reducing autophagy capacity in dying neurons/neurons) [@cuervo]

[@xu2024]. [^8]

Autophagosome-Lysosome Fusion Defects

Even when autophagosomes form successfully in AD neurons/neurons), their fusion with lysosomes is impaired. This defect involves: (1) reduced SNARE protein (STX17, SNAP29, VAMP8) expression; (2) altered membrane lipid composition due to disrupted sphingolipid metabolism; and (3) presenilin 1 mutations that impair lysosomal acidification and trafficking. The resulting accumulation of immature autophagic vacuoles — prominently observed in dystrophic neurites around amyloid plaques — represents a histopathological hallmark of AD (Nixon et al., 2005) [^9]

[@patel2024].

Lysosomal Dysfunction

Lysosomal Acidification Failure

Optimal lysosomal function requires maintaining luminal pH at 4.5–5.0 through the vacuolar H⁺-ATPase (v-ATPase) proton pump. presenilin-1 — better known as the catalytic subunit of gamma-secretase — has an independent function in lysosomal acidification: it facilitates v-ATPase assembly and targeting to lysosomes. Familial AD-associated PSEN1 mutations impair this function, raising lysosomal pH and reducing cathepsin activity (Lee et al., 2010). Recent studies confirm that lysosomal pH is elevated in sporadic AD neurons/neurons) as well, suggesting broader relevance beyond familial cases

[^6].

Cathepsin Dysregulation

Lysosomal cathepsins (D, B, L) are the primary proteases responsible for degrading autophagy substrates. Cathepsin D, the principal aspartyl protease, shows paradoxically increased expression but reduced activity in AD brains, reflecting impaired lysosomal maturation. Cathepsin B has dual roles: degrading Aβ42 (protective) but also contributing to BACE1

[@cuervo].

Lysosomal Membrane Permeabilization

Lysosomal membrane permeabilization (LMP) occurs in AD neurons/neurons) due to Aβ-induced oxidative stress, calcium overload, and lipid peroxidation. LMP releases cathepsins and other hydrolases into the cytoplasm, activating apoptotic cascades and the NLRP3 inflammasome]. Galectin-3, which detects damaged lysosomal membranes, is elevated in AD brains and correlates with neuronal loss

[^8].

Chaperone-Mediated Autophagy

CMA selectively degrades cytosolic containing a KFERQ pentapeptide motif, recognized by the chaperone Hsc70 and delivered to lysosomes through the receptor LAMP-2A. CMA activity declines with aging and is further impaired in AD (Cuervo & Wong, 2014)

[^9].

LAMP-2A Deficiency

LAMP-2A expression is reduced in AD brains, limiting CMA substrate delivery to lysosomes. Since tau contains KFERQ-like motifs and is a CMA substrate, LAMP-2A deficiency directly impairs tau clearance. Transcriptional upregulation of LAMP-2A through retinoic acid receptor signaling enhances CMA and reduces tau pathology in experimental models [@bourdenx2024].

CMA-Macroautophagy Crosstalk

CMA and macroautophagy exhibit compensatory regulation: when one pathway fails, the other is upregulated. In AD, both pathways are impaired, eliminating this compensatory mechanism and creating a catastrophic failure of protein quality control. This dual failure distinguishes AD from normal aging, where CMA decline is partially compensated by maintained macroautophagy

[@ndungu2024].

Impact on Amyloid and Tau Pathology

Amyloid-Beta Processing

Autophagosomes contain the enzymatic machinery for Aβ generation — APP/app-protein), BACE1/bace1) Yu et al., 2005

[@jiang2025].

Tau Aggregation and Spread

Dysfunction of the autophagy-lysosomal pathway directly promotes tau//tau pathology through impaired clearance and enhanced propagation (Lee et al., 2013):

• CMA impairment: Disease-modified tau (acetylated, truncated) evades chaperone-mediated autophagy via the LAMP-2A receptor, leading to cytoplasmic accumulation
• Autophagosome accumulation: Tau(//tau oligomers impair autophagosome-lysosome fusion, creating a feed-forward cycle of aggregate buildup
• Secretion and spreading: When intracellular degradation fails, tau is secreted via unconventional pathways (exosomes/exosomes), ectosomes), facilitating prion-like trans-neuronal propagation
• Lysosomal rupture: Tau fibrils can rupture lysosomal membranes, releasing cathepsins and activating NLRP3 inflammasome in microglia (Bhatt et al., 2020)
• Therapeutic targeting: TFEB activators, trehalose, and CMA enhancers enhance tau clearance in preclinical models

Therapeutic Approaches

mTOR Inhibitors

Rapamycin and rapalogs (everolimus, temsirolimus) enhance macroautophagy and reduce amyloid and tau pathology in AD mouse models. However, chronic mTOR inhibition causes immunosuppression, impaired wound healing, and metabolic disturbances. Low-dose intermittent rapamycin dosing may provide autophagy enhancement with acceptable tolerability and is being evaluated in clinical trials

[@xu2024].

mTOR-Independent Autophagy Inducers

Several FDA-approved drugs enhance autophagy through mTOR-independent , offering potential for repurposing. Trehalose activates TFEB (transcription factor EB), the master regulator of lysosomal biogenesis and autophagy gene expression. Lithium inhibits inositol monophosphatase, inducing autophagy via IP3 reduction. Metformin activates AMPK, which both inhibits mTORC1 and directly phosphorylates ULK1. [Carbamazepine and valproic acid also enhance autophagic flux through distinct

[@patel2024].

TFEB Activation

TFEB coordinates expression of genes controlling lysosomal biogenesis, autophagosome formation, and cargo degradation. TFEB is sequestered in the cytoplasm by mTORC1-mediated phosphorylation; upon nuclear translocation, it upregulates the entire autophagy-lysosomal pathway. Pharmacological TFEB activators and gene therapy delivering TFEB to neurons/neurons) show robust effects in AD models, enhancing both Aβ and tau clearance (Martini-Stoica et al., 2016)

[^6].

Lysosomal Function Enhancement

Strategies to restore lysosomal function include: acidifying agents that compensate for v-ATPase deficiency; cathepsin D activators; lysosomal membrane stabilizers (HSP70 chaperone); and gene therapy delivering functional lysosomal enzymes. These approaches are complementary to autophagy induction and address the downstream degradative bottleneck

[@cuervo].

Biomarker Potential

autophagy-lysosomal dysfunction are emerging for AD diagnosis and monitoring. CSF levels of cathepsin D, LAMP-1, and LAMP-2 are altered in AD patients. Blood-based assays for LC3-II (autophagosome marker) and p62 (autophagy substrate/receptor) reflect autophagic flux. These markers may identify patients who would benefit most from autophagy-enhancing therapies and monitor treatment response

[^8].

See Also

• All Mechanisms

Background

The study of autophagy Lysosomal Pathway Dysfunction In Alzheimer's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development

[^9].

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [@bourdenx2024].

External Links

• PubMed - Biomedical literature
• Alzheimer's Disease Neuroimaging Initiative - Research data
• Allen Brain Atlas - Brain gene expression data

<!-- ci040-visuals:autophagy-pathway -->

Visual Summary

Pathway Flowchart

SVG Diagram

!autophagy-pathway pathway diagram

Figure: autophagy pathway pathway schematic generated for NeuroWiki.

Recent Research Updates (2024-2025)

Key developments in autophagy-lysosomal pathway research for Alzheimer's disease:

TFEB/tfeb) activation approaches: A 2024 study demonstrated that small-molecule TFEB activators can restore lysosomal function and reduce Aβ and [tau](/entities/tau-protein) pathology in [APP](/entities/app-protein)/app-protein)/PS1 mice, with translational potential for human trials[@bourdenx2024].

CMA and APOE4 interaction: Research in 2024 identified that APOE4 disrupts chaperone-mediated autophagy (CMA) by competing with substrates for LAMP-2A binding, providing a mechanistic link between genetic risk and lysosomal dysfunction[@ndungu2024].

Mitophagy-lysosomal crosstalk: Studies in 2025 revealed that PINK1/Parkin-mediated mitophagy defects exacerbate lysosomal stress in AD neurons, suggesting combination therapies targeting both pathways[@jiang2025].

Blood-based lysosomal : A 2024 clinical study validated lysosomal enzyme panels (cathepsin D, LAMP-1, LAMP-2) as peripheral correlating with CSF Aβ42/40 ratios and cognitive decline[@xu2024].

mTOR-independent autophagy inducers: Clinical trials with mTOR-independent autophagy enhancers (trehalose derivatives, SMER28 analogs) showed improved safety profiles in phase 1 studies, advancing toward AD-specific indications[@patel2024].

Autophagy-Lysosomal Pathway in Alzheimer's Disease Pathogenesis

The autophagy-lysosomal pathway (ALP) is a critical cellular degradation system that maintains protein homeostasis by engulfing cytoplasmic components into double-membrane autophagosomes and delivering them to lysosomes for degradation. In Alzheimer's disease, ALP function becomes progressively impaired at multiple stages, contributing to the accumulation of toxic including amyloid-beta plaques and hyperphosphorylated tau neurofibrillary tangles. Autophagy is essential for synaptic function, and its impairment in AD leads to synaptic loss and cognitive decline. The [presenilin-1](/entities/psen1) mutation associated with familial AD causes lysosomal acidification defects that impair autophagic flux. Rescue of autophagy through pharmacological manipulation reduces amyloid and tau pathology in animal models, highlighting therapeutic potential.

Therapeutic Modulation of Autophagy-Lysosomal Pathway

Multiple therapeutic strategies target ALP dysfunction in Alzheimer's disease. mTOR inhibitors such as rapamycin and everolimus enhance autophagy induction and have shown promise in reducing AD pathology in preclinical models. Natural compounds including resveratrol, curcumin, and EGCG activate autophagy through AMPK-dependent pathways. Lysosomal enhancers that restore cathepsin activity improve clearance of toxic . Gene therapy approaches delivering autophagy-inducing such as Beclin-1 or TFEB are under investigation. Combination therapies targeting multiple steps of the ALP may prove most effective. Clinical trials of autophagy modulators in AD are ongoing, with measuring autophagic flux as outcome measures.

Autophagy-Lysosomal Pathway and Neuroinflammation

The autophagy-lysosomal pathway intersects with neuroinflammatory processes in Alzheimer's disease through multiple . Autophagy regulates the secretion of inflammatory cytokines and damage-associated molecular patterns (DAMPs). Impaired ALP in [microglia](/cell-types/microglia-neuroinflammation) leads to inflammasome activation and excessive cytokine production. Tau pathology activates autophagy in microglia, and autophagy disruption promotes inflammatory responses. Conversely, chronic neuroinflammation suppresses autophagy through mTOR activation. Therapeutic targeting of both autophagy and neuroinflammation may provide synergistic benefits. Understanding these interactions informs comprehensive treatment strategies for AD.

Autophagy in Specific AD Brain Regions

Autophagy-lysosomal dysfunction varies across brain regions in Alzheimer's disease, correlating with regional vulnerability to pathology. The [hippocampus](/brain-regions/hippocampus), critical for memory formation, shows early and severe autophagic-lysosomal disruption. [Entorhinal cortex](/brain-regions/entorhinal-cortex) and prefrontal [cortex](/brain-regions/cortex) also demonstrate significant ALP impairment. Autophagy in the locus coeruleus is affected early given its vulnerability to tau pathology. Regional differences in lysosomal enzyme expression, autophagy protein levels, and cellular energy status contribute to differential vulnerability. Understanding region-specific autophagy defects informs targeted therapeutic approaches and biomarker development for early AD detection.

Biomarkers of Autophagy-Lysosomal Pathway Dysfunction

Measuring ALP function in patients provides diagnostic and monitoring tools for Alzheimer's disease. Cerebrospinal fluid (CSF) levels of autophagy-related including Beclin-1, LC3, and p62 reflect brain autophagy status. Decreased Beclin-1 and increased p62 in CSF correlate with disease severity. Imaging using PET ligands that bind to autophagic vesicles are under development. Peripheral blood mononuclear cell autophagy measurements show promise as minimally invasive . These enable patient stratification for autophagy-targeted therapies and treatment response monitoring.

Autophagy-Lysosomal Pathway Interactions with Other AD Mechanisms

The autophagy-lysosomal pathway interacts extensively with other AD-relevant cellular . Mitochondrial dysfunction impairs autophagy, creating a vicious cycle of proteostasis failure. ER stress activates autophagy through the [unfolded protein response](/entities/unfolded-protein-response). Cellular energy depletion activates AMPK, which stimulates autophagy. Amyloid-beta itself disrupts autophagy at multiple points, including autophagosome-lysosome fusion. Tau pathology interferes with lysosomal function and autophagic clearance. These interactions suggest that comprehensive AD treatment must address multiple interconnected pathways.

Autophagy-Lysosomal Pathway in Animal Models of AD

Transgenic animal models of Alzheimer's disease have revealed essential insights into ALP dysfunction. APP/PS1 mice show age-dependent autophagic vacuole accumulation in neurons. 3xTg-AD mice demonstrate impaired autophagic flux and lysosomal depletion. Tau P301S mice exhibit autophagy disruption in neurons and glia. Genetic manipulation of autophagy genes modifies amyloid and tau pathology in these models. Beclin-1 haploinsufficiency increases amyloid deposition, while autophagy enhancement reduces pathology. These models enable therapeutic screening and mechanistic studies of ALP-targeted interventions.

Clinical Implications and Future Directions

Translating autophagy-lysosomal pathway insights into clinical treatments requires addressing several challenges. [Blood-brain barrier](/entities/blood-brain-barrier) penetration limits many autophagy-modulating compounds. Timing of intervention may be critical, as autophagy enhancement could have different effects at different disease stages. Combination therapies targeting multiple pathways may prove most effective. Biomarker development for patient selection and response monitoring is essential. Future research should focus on identifying druggable targets within the ALP, developing brain-penetrant modulators, and conducting early-intervention clinical trials.

Autophagy Regulation by Cellular Stress

Multiple cellular stress pathways converge on autophagy modulation in Alzheimer's disease. Oxidative stress activates autophagy through Nrf2-dependent transcription of autophagy genes. Energy deprivation activates AMPK, which phosphorylates and activates ULK1 kinase complex. Heat shock assist in protein refolding and autophagy regulation. The integrated stress response (ISR) modulates autophagy through eIF2alpha phosphorylation. These stress-response pathways represent therapeutic targets for restoring autophagic flux in AD.

References

[Molecular mechanisms underlying exercise-enhanced autophagy in improving neuroplasticity in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41907848/) (Frontiers in aging neuroscience, 2026, PMID:41907848)

[Presenilin-dependent regulation of neuronal tau pathology via the autophagy and proteasome pathways.](https://pubmed.ncbi.nlm.nih.gov/41863024/) (Acta neuropathologica communications, 2026, PMID:41863024)

[Flavonoids of Ziziphora clinopodioides improve Alzheimer's cognitive impairment and inhibit NLRP3 inflammasome activation via autophagy-lysosome pathway.](https://pubmed.ncbi.nlm.nih.gov/41818943/) (Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026, PMID:41818943)